Leading a new era in radiopharmaceuticals

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.

Telix’s deep pipeline for prostate, kidney, brain (glioblastoma), and hematologic cancers, and rare diseases is underpinned by a reliable and secure global supply chain, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 20 clinical trials underway worldwide.

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline

Clinical Pipeline

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline  

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix®

Illuccix®

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix®  

Join our team driving innovation across cancer and rare diseases.

View opportunities

Careers at Telix

Join our team driving innovation across cancer and rare diseases.

View opportunities   

Latest News

See all

HRH Princess Astrid of Belgium visits Telix’s New European Manufacturing Facility in Brussels South

Telix has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company’s recently inaugurated production facility, in Brussels South (Seneffe) in the Wallonia region of…

Read more

Telix collaborates with Eckert & Ziegler and RefleXion Medical to Expand Treatment Options for Prostate Cancer Patients

Read more

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

Read more

Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

Read more